Science

Inside the Scientific Arsenal: The High-Speed Racetrack That Can Make Proteins Explode

Ben Orsburn, Ph.D., stood in the middle of a 180-square-foot laboratory, speaking over the white noise that flooded the room. The source of the din—large, desk-sized objects called mass spectrometers—filled nearby rows of lab benches. Orsburn pointed to one along the periphery of the room, a white-and-black box with the words “Orbitrap Fusion” emblazoned on the front in small blue text.

Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.

“Something Just Clicked”: Partnership Pushes New Class of Cancer Drug Toward Human Trials

Serguei Kozlov, Ph.D., doesn’t recall if it was he who first contacted clinician Udo Rudloff, M.D., Ph.D., or Rudloff who contacted him. He just knows that their resulting two-year collaboration, which recently moved a first-in-class drug for metastatic cancer toward clinical trials, is one of the best he’s ever had.

NICBR Winter Symposium Focuses on Novel Therapeutics Research

Attendees packed the Building 549 Conference Center for the National Interagency Confederation for Biological Research (NICBR) Winter Symposium, the latest in a series that aims to foster collaboration between its eight member agencies. Each symposium focuses on a specific theme, with the most recent event organized around novel therapeutics.

“A Stellar and Beautiful Building”: 538 Renovation Reaches Completion

When NCI at Frederick began receiving royalty money from the HPV vaccine research by Doug Lowy, John Schiller, and colleagues, a portion was set aside for facilities renovations on the NCI at Frederick campus. One of the first spaces slated for renovation was Building 538, which was mainly occupied by Center for Cancer Research (CCR) scientists.

Inside the Scientific Arsenal: A Nobel-Prize-Winning Method for 3D Modeling

Every Monday morning, Ulrich Baxa, Ph.D., and his colleagues enter their Gaithersburg, Md., laboratory and begin calibrating their Titan Krios, a massive, $7-million transmission electron microscope that can capture high-definition images at near-atomic magnification. They load several flash-frozen biological samples into the Krios and, by 5 p.m., program the instrument to collect data. As the team leaves for the evening, the Krios begins shooting beams of energy into the samples and taking photos.

Inside the Scientific Arsenal: The Two-Armed Tool That’s Faster Than a Scientist

Sitting at a computer in an NCI at Frederick laboratory, Todd Hartley writes an automated method for an experiment. With a final swipe of the mouse, he clicks an on-screen button that says “Run.” The large device sitting to his left, a Biomek FXP Laboratory Automation Workstation, whirrs to life. A robotic arm hovers over a deck containing various microplates then lowers a group of pipette tips to draw liquid from a reservoir, raises and moves again, and deposits the fluid in a nearby microplate with superhuman accuracy.

Researchers Identify Possible Reason for Loss of Brain Function in Patients with ALS

A team of scientists in NCI at Frederick’s Center for Cancer Research Mouse Cancer Genetics Program and their collaborators at the University of Florence have identified a link between the presence of a growth factor receptor and cognitive impairments in patients with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).